TRVI Trevi Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1563880 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY-8.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-24.7%
ROA-23.8%
ROIC (approx.)-27.2%
Asset turnover—
Leverage & solvency
Liabilities / assets2.6%
Debt / equity0.00x
Current ratio38.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $33.48M | $39.38M | $23.68M | $19.83M | $22.98M |
| SG&A expense | $15.85M | $12.15M | $10.24M | $10.07M | $9.49M |
| Operating income | -$49.33M | -$51.52M | -$33.92M | -$29.91M | -$32.48M |
| Interest expense | $0 | $4,000 | $391,000 | $1.16M | $1.20M |
| Pretax income | -$42.82M | -$47.94M | -$29.10M | -$29.19M | -$33.96M |
| Income tax | -$64,000 | -$30,000 | -$32,000 | -$36,000 | -$21,000 |
| Net income | -$42.76M | -$47.91M | -$29.07M | -$29.15M | -$33.94M |
| EBITDA | -$49.18M | -$51.38M | -$33.80M | -$29.86M | -$32.43M |
| EPS (basic) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 |
| EPS (diluted) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 |
| Weighted avg. shares (diluted) | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M |
| Balance sheet | |||||
| Cash & equivalents | $18.91M | $34.10M | $32.40M | $12.59M | $36.83M |
| Short-term investments | $169.35M | $73.53M | $50.57M | $107.92M | — |
| Current assets | $191.66M | $109.43M | $87.55M | $122.62M | $37.96M |
| PP&E, net | $178,000 | $157,000 | $216,000 | $170,000 | $53,000 |
| Total assets | $193.44M | $110.90M | $89.40M | $123.02M | $38.48M |
| Current liabilities | $9.75M | $10.51M | $5.82M | $13.40M | $12.72M |
| Total liabilities | $10.20M | $11.26M | $6.86M | $15.56M | $21.40M |
| Shareholders' equity | $183.24M | $99.64M | $82.55M | $107.46M | $17.07M |
| Shares outstanding | 128.31M | 93.60M | 68.28M | 59.94M | 28.51M |
| Cash flow statement | |||||
| Operating cash flow | -$42.09M | -$38.26M | -$31.71M | -$28.18M | -$28.95M |
| Capital expenditure | $12,000 | $35,000 | $137,000 | $159,000 | — |
| Free cash flow | -$42.10M | -$38.29M | -$31.85M | -$28.33M | — |
| Investing cash flow | -$94.11M | -$21.53M | $59.43M | -$107.37M | — |
| Financing cash flow | $121.01M | $61.48M | -$7.91M | $111.31M | $20.77M |
| Depreciation & amortization | $144,000 | $147,000 | $123,000 | $43,000 | $50,000 |
| Stock-based compensation | $5.18M | $3.59M | $2.25M | $2.33M | $2.54M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.